vitamin D metabolism in patients with treatment for Stage 3 CKD

CKD Treatment

Although the effects of chronic kidney disease (CKD) become more severe as the disease progresses, there are a number of options that can be effective in managing the disease if it is detected early. This is one of the reasons why knowing what symptoms to look for and having a good understanding of CKD can help patients begin managing the disease earlier and therefore get a much better start at maintaining kidney function and slowing the progression of disease.

High blood pressure can be treated effectively. Your doctor may prescribe blood pressure medication. Blood pressure medicines such as angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are able to correct blood pressure effectively. Not only this but, it has been found that they provide greater protection of the kidneys than other medicines which lower blood pressure to similar levels.

There are many  of treatment Stage 3 CKD.  Two of the commonest causes are high blood pressure and ageing of the kidneys. Very few of the causes of CKD are completely curable, so it is often not necessary to do extensive tests to find a cause, so long as blood tests show the kidney function is stable.

Patients with treatment for Stage 3 CKD are generally affected by secondary hyperparathyroidism (SHPT).Recently, new studies indicate that fibroblast growth factor 23 may play a central role in the regulation of phosphate-vitamin D metabolism in patients with treatment for Stage 3 CKD.

These new insights into the pathogenesis of SHPT will possibly improve the treatment of this condition in patients with treatment for Stage 3 CKD. The ‘modern’ treatment for Stage 3 CKD T in CKD patients consists of free-calcium and aluminium phosphate binders, vitamin D receptor activators and calcimimetics. However, calcium- and aluminium-based phosphate binders and calcitriol are therapeutic tools that are not without complications, including increasing the risk of cardiovascular calcification in patients with CKD. This review summarizes the current understanding and evidence supporting strategies for SHPT treatment in treatment for Stage 3 CKD patients, with particular focus on the elderly, although specific guidelines for control of this disorder in this age group are lacking.

http://www.sjzkidneyhospital.com/tags.php?/CKD+Treatment/